Ellen L. Berg
Ellen L. Berg, PhD, is Chief Scientific Officer for Translational Biology at Eurofins Discovery and leads data science efforts for the company’s reference data assets including the BioMAP® platform of human primary cell based assays and predictive analysis tools. Dr. Berg was a founder and CSO of BioSeek, acquired by DiscoverX and subsequently Eurofins, and previously led a research team at Protein Design Labs, developing novel therapeutic antibodies for inflammatory diseases. She has been a principal at Alto Predict since 2012. She received her PhD from Northwestern University and was a postdoctoral fellow at Stanford University in the Department of Pathology. Dr. Berg has expertise in in vitro models of human disease and tissue biology, phenotypic drug discovery and data analytics. She holds a number of patents in the field of inflammation and cardiovascular drug discovery, and has authored over 80 publications. She has served in various positions with the Society of Laboratory Automation and Screening, is a member of the Society of Toxicology and a board member of the American Society for Cellular and Computational Toxicology. Her research interests include systems biology, chemical biology, drug and toxicity mechanisms of action, phenotypic drug discovery, alternative methods for animal testing, and predictive methods for human efficacy and safety outcomes.